A variety of approaches has demonstrated that interfering with tumor -induced angiogenesis may be an effective strategy in cancer therapy. However, it is likely that to be most effective such strategies will require extended suppression of the angiogenic process. Gene therapy offers a possible approach to achieve sustained release of a therapeutically potent transferred gene product. In the present study the angiogenesis inhibitor endostatin was expressed through a recombinant adeno -associated viral ( rAAV ) vector and shown to be biologically active in vitro and in vivo. Intramuscular injection of rAAV -HuEndo ( 1Â10 9 i.u. ) led to a sustained serum endostatin level of $35 -40 ng / mL. This endostatin level was sufficient to inhibit tumor cell -induced angiogenesis and to suppress both the initiation and subsequent growth of a human colorectal cancer model.
A ngiogenesis, the formation of new blood vessels from existing capillaries, is a sequence of events of key importance in a broad array of pathologic processes including the growth and dissemination of malignant tumors. 1 Solid tumors not only need to stimulate the growth of their own cells but also to initiate a vascular network by neovascularization. Indeed, the degree of vascularization of a tumor has been associated with its aggressiveness and for several tumor types may provide the most reliable prognostic indicators of clinical outcome. 2 -4 Because traditional cancer treatments often fail to achieve tumor control, 5 new strategies aimed at affecting tumor growth by blocking the angiogenic process have emerged as a new direction for cancer treatment. 6 As normal endothelium has an exceedingly slow turnover rate, antiangiogenic or vascular targeting therapies hold the possibility of high and selective efficacy, low toxicity, and minimal potential for developing resistance. 5 -9 Among the factors that regulate angiogenesis, endostatin, a 20 -kDa C -terminal proteolytic fragment of collagen XVIII, has been found to be a potent inhibitor of angiogenesis. In vitro studies have shown that endostatin can inhibit endothelial cell proliferation and migration and induce endothelial cell apoptosis. 10, 11 In vivo, the systemic administration of recombinant endostatin resulted in growth inhibition or regression in a number of different tumor models. 10,12 -15 Given these encouraging results, a variety of approaches has been taken to modulate levels of endostatin in an attempt to impact tumor growth by targeting its vascular network.
To date, therapeutic strategies with endostatin have focused primarily on the administration of the antiangiogenic protein. A potential problem in translating this approach into the clinic is the difficulty and cost of producing sufficiently large amounts of biologically active protein for chronic treatment. Moreover, endostatin, a protein drug, tends to have a short half -life in vivo, thus posing concerns about maintaining therapeutically effective serum levels. Gene therapy, which can deliver gene cassettes encoding for therapeutic gene products, may provide a solution to the problem. Indeed Sauter et al successfully delivered endostatin using an adenovirus construct. 16 However, concerns about adenovirus therapy remain and, consequently, the development of a nonpathogenic, nonimmunogenic adenovirus that is capable of long -term expression of transferred genes is still ongoing. 17 Alternatively, the employment of other viral delivery systems may be warranted. Among the variety of therapeutic vectors available for consideration, adeno-associated virus (AAV ) has a number of features that may prove advantageous for antiangiogenic therapy. They include an absence of any pathology in humans or animals, low immunogenicity, broad host tropism, and stable expression of transgenes in vivo from a variety of tissues such as muscle, liver, and neuronal cells. 18, 19 As a parvovirus, it is naturally replication defective, requiring coinfection with a helper virus (adenovirus or herpesvirus ) for replication. In addition, AAV vector constructs have been used to stably transduce tissues in vivo and lead to long -term expression of the desired transgene including the sustained secretion of serum proteins such as 1-antitrypsin, factor IX or leptin. 20 -23 In an angiogenic therapy setting the utilization of AAV as a viral delivery system offers the potential of providing enduring benefit from a single or limited number of treatments.
Conditioned media from cells transduced with recombinant adeno-associated viral (rAAV ) expressing endostatin have been shown to inhibit capillary endothelial cell proliferation in vitro. 15, 24 In the present study, we evaluated the antiangiogenic and antitumor effects of elevating serum endostatin levels using AAV-mediated delivery and expression in mice bearing a human colorectal cancer model.
Materials and methods

Cell culture
The human colon cancer cell line HT29 and E1A /E1B transformed human embryonic kidney cell 293 were grown in Dulbecco's modified minimum essential medium ( DMEM, Gibco, Grand Island, NY ) supplemented with 10% fetal bovine serum ( FBS, Gibco), 1% penicillinstreptomycin (Gibco) and 1% 200 mmol /L L -glutamine ( Gibco ). Human umbilical vein endothelial cells ( HUVEC ) were grown in F -12K medium (Sigma, St. Louis, MO ) supplemented with 30 g /mL endothelial cell growth supplements (Sigma ), 100 g/ mL heparin ( Gibco ), 10% FBS, 1% penicillin -streptomycin, and 1% 200 mmol /L L -glutamine. The mouse heart endothelial cell line (MHE ) was a gift from Dr Robert Auerbach ( University of Wisconsin ). MHE cells were grown in DMEM supplemented with 10% heat -inactivated FBS, 1% penicillin -streptomycin, and 1% 200 mmol /L L -glutamine.
rAAV construction and production
Human endostatin was amplified from a cDNA library by PCR. The human growth hormone signal peptide was engineered as a secretion signal. This construct was cloned into a rAAV plasmid (pTR -UF21 ) under the control of a CMV-enhancer chicken -actin hybrid promoter ( Fig 1) . The parental plasmid pTR -UF21 containing the green fluorescence protein (GFP ) as a transgene served as a control. A NeoR gene cassette was inserted as a selection marker. All the constructs were sequenced to confirm correct sequences by the DNA sequence service in the Center for Mammalian Genetics at the University of Florida. rAAV vectors were produced by a two-plasmid transfection 25 and purification method. 26 Briefly, 293 cells at 70-80% confluence were transfected with the rAAV plasmid plus the helper plasmid ( pDG ) by standard CaCl 2 technique for a period of 72 hours. After harvesting the cells, three freeze / thaw cycles were applied and the sample was treated with DNase (Benzonase ). Following centrifugation the rAAV was purified using a discontinuous iodixanol gradient followed by a heparin sulfate column separation. The virus then was concentrated in a Millipore concentrator (100 -kDa cut off) and tittered.
Generation of stable cell lines by rAAV transduction
HT29 and 293 cells were grown to $80% confluence, trypsinized and counted. An aliquot containing 10 4 cells was then suspended in 50 l of serum and antibiotic -free medium. rAAV vectors containing the endostatin or GFP cassettes were then added at a multiplicity of infection ( MOI ) of 10,000 and incubated at 378C for 3 hours. Subsequently the cells were plated in 96 -well dishes in appropriate medium. Following exposure the cells were grown and expanded for 2 weeks before starting the cell selection by adding 1 mg /mL G418 (Gibco). After 1 week Figure 1 Construction of rAAV vector. The expression cassette of endostatin, which consists of a CMV -enhancer chicken -actin hybrid promoter, a human growth hormone signal peptide, and human endostatin cDNA, was cloned into a rAAV plasmid ( pTR -UF21 ). Cancer Gene Therapy AAV mediated gene transfer of endostatin W Shi et al of G418 treatment, the cells were plated at low density ( 100 cells/100 -mm dish ) for isolation of single colonies. Colonies expressing GFP were identified under a fluorescence microscope and quantified by flow cytometry. Colonies expressing endostatin were screened for endostatin expression by immunoassay. Stable cell lines were maintained in DMEM containing 500 g/ mL G418.
Endostatin enzyme immunoassay
In vitro, tumor cells were plated (1Â10 6 per well in six -well dishes) with 2 mL of appropriate growth medium and incubated for 24 hours. In vivo, blood samples were collected by cardiac puncture and serum separated by centrifugation. In both cases, a 100 -l sample was analyzed using a human endostatin immunoassay kit (Cytimmune Sciences, College Park, MD ).
Production of endostatin -conditioned medium
Stable 293 clones expressing human endostatin or GFP were grown to 80% confluence in 10% FBS containing DMEM with 500 g/mL G418. The medium was then removed and the plates were washed three times with DMEM without G418. Fresh DMEM medium containing 1% FBS was then added. The cells were incubated for another 24 hours before determining the endostatin levels by immunoassay. The conditioned medium was collected and stored in aliquots at À 808C.
Endothelial cell proliferation assay
HUVEC and MHE cells were set at 1Â10 5 cells in six -well dishes and allowed to attach overnight. The medium was then replaced with conditioned medium containing known concentrations of human endostatin. After an incubation period of 3 days, the number of HUVEC and MHE cells were counted using a hemocytometer.
Endothelial cell migration assay
HUVEC and MHE cells were grown in T-150 flasks to 80% confluence. The cells were then stained in medium containing 10 g/ mL Di -I ( Molecular Probes, Eugene, OR ) for 24 hours. Subsequently the cells were washed four times with PBS, collected, and counted. Cells (5Â10 4 ) were then plated on FluoroBlok inserts (Becton Dickinson, Franklin Lakes, NJ ) before placing them into wells of conditioned media containing human endostatin. Cells were incubated for a period of 24 hours. After incubation, the cells that migrated through the membrane were determined by measuring the fluorescence on the bottom of the membrane using a CytoFluor 4000 plate reader (Perceptive BioSystems, St. Paul, MN ).
Intradermal angiogenesis assay
In situ tumor-induced angiogenesis was evaluated using an intradermal angiogenesis assay as first described by Auerbach et al. 27 Briefly, 5Â10 4 tumor cells suspended in 10 l saline were inoculated intradermally at four sites on the ventral surface of nude mice using a 10-l Hamilton microsyringe. Three days later, the mice were killed by CO 2 asphyxiation and the skin was separated carefully from underlying muscle. Vessels intersecting the edge of the tumor inoculates were counted using a dissecting microscope. Scoring of all of the reaction areas was carried out at the same magnification ( Â5 ) and only vessels readily detected at this magnification were counted. All the animals in the experiments were precoded and vessel counts in each animal were scored twice. The resultant data points for each Vessel number Figure 4 HT29 parental cells and stable HT29 clones expressing GFP or endostatin were injected ( 5Â10 4 ) intradermally at four sites in the ventral surfaces of nude mice. Three days later the skin was removed and the number of vessels induced were counted using a dissecting microscope. Each solid cycle represents one injection site, the bars show the median of 16 sites per group. The number of vessels induced by AAV -HuEndo -transfected cells were significantly lower ( P < .05, Wilcoxon rank sum test ).
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In vivo tumor cell and rAAV vector injections
Female nude mice (NCR, nu/ nu), age 6-8 weeks were obtained from Jackson Laboratories ( Bar Harbor, ME ) and maintained under specific pathogen -free conditions ( University of Florida Health Science Center Vivarium ) with food and water supplied ad libitum. To establish xenografts, animals were inoculated subcutaneously in a single flank with 2Â10
6 tumor cells suspended in 0.9% saline. To deliver the gene therapy, 20 l of rAAV-GFP or rAAV-HuEndo viral vectors at various doses were injected into the hind leg tibialis anterior muscles percutaneously.
Tumor growth delay assay
Once established, tumors were measured using calipers and volumes were approximated by the formula, volume= 1/ 6ab 2 , where a and b represent two perpendicular tumor diameters. Tumor volumes were measured every 2 days. The times for the tumors in the various treatment groups to grow to 200 mm 3 and from 200 to 1000 mm 3 were recorded and compared (Wilcoxon rank sum test ).
Immunohistochemistry of CD31
Tumor microvessels were stained using a mouse monoclonal antibody to the CD31 antigen on endothelial cells (Beckman Coulter, Brea, CA ). Frozen sections ( 10 m ) were cut on a cryostat, air-dried, and fixed in acetone at 48C for 10 minutes. The primary antibody was applied at a dilution of 1:50 overnight at 48C followed by standard washing. A secondary antibody conjugated with Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA ) was then applied for 1 hour at room temperature followed by standard washing. The slides were air dried and kept in the dark at 48C until evaluation.
Histology and vascular assessment
Hoechst 33342 (bisBenzimide, Sigma) was used to assess the functional vessels of the tumors. The compound was dissolved in sterile saline just before use and injected intravenously at the dose of 40 mg /kg. One minute later the mice were killed, the tumors removed and cut in half. One half was immediately immersed in liquid nitrogen; the other was fixed in 10% formalin. Standard hematoxylin -eosin ( H&E ) staining was carried out on the formalin -fixed tumor specimens. The sections were viewed and captured using a Zeiss Zxiophot 2 microscope ( Carl Zeiss Jena, Jena Germany ) with a Sony DXC970 color camera (Sony, Tokyo, Japan ). Entire tumor sections were reconstructed by tiled field mapping and the total tumor area as well as the area of tumor necrosis was determined using a MCID5.5 imageanalysis program (Imaging Research, Ontario, Canada). Estimates of tumor angiogenesis were made on frozen sections stained with CD31 using the Chalkley counting method on vessel hot -spots. 28 Briefly, the three most vascular areas ( hot spots ) were identified subjectively. The vessels then were counted at high magnification (Â250 ) by applying a 25 -point Chalkley grid eyepiece ( McCrone Microscopes and Accessories, Westmont, IL ) to each hotspot area and recording the number of points on Hoechst 33342 and CD31 -highlighted microvessels. 29 The Chalkley count for an individual tumor was the mean of 10 random fields. All the animals in the studies were precoded and tumor sections were counted blinded. Serum HuEndo level (ng/ml) Figure 5 Human endostatin levels determined in the sera of nude mice injected with 293 cells that stably overexpress HuEndo ( 293 -HuEndo ) at various times after injection. Endostatin levels were determined by immunoassay. Each datum point represents the mean ± SE of three animals. Figure 6 The effect of increased serum endostatin level on the ability of HT29 cells to induce blood vessels in an intradermal angiogenesis assay. Nude mice were injected intramuscularly with 1Â10 7 cells derived from stable 293 clones expressing either GFP or human endostatin gene. Twenty -four hours later, 5Â10 4 HT29 were injected intradermally at four sites into the ventral surface of the nude mice. Three days later the skin was removed and the number of vessels induced were counted using a dissecting microscope. Each solid cycle represents one injection site, the bars show the median of 16 sites per group. P < .05, 293 -HuEndo group versus untreated or 293 -GFP groups.
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collected from this stable 293 -HuEndo clone and evaluated its effect in both human (HUVEC ) and mouse (MHE ) endothelial cell cultures. The results showed a dosedependent inhibition of endothelial cell growth ( Fig 2 ) . For example, a 4-day treatment at 50 ng/mL inhibited HUVEC and MHE proliferation by 34% ( P <.05 ) and 25% ( P <.05 ), respectively. Similarly, the recombinant endostatin suppressed the migratory potential of the endothelial cells ( Fig 3) . This effect also was found to be endostatin dose dependent; 50 ng /mL inhibited the migration of HUVEC by 24% ( P <.05 ) and that of MHE by 26% ( P< .05 ). Importantly, conditioned media from 293 cells transduced with a control rAAV-GFP vector did not influence endothelial cell proliferation or migration. To test whether recombinant endostatin produced by rAAV-mediated transduction had a direct inhibitory effect on endothelial cell proliferation and migration in vivo, a single stable HT29 clone (HT29 -HuEndo cells) that overexpressed endostatin at $56 ng/ mL / 10 6 cells per day was injected intradermally and its ability to induce blood vessels was assessed using an in vivo angiogenesis assay (Fig 4 ) . The number of vessels induced by parental HT29 and GFP expressing HT29 cells were similar. However, HT29 -HuEndo cells were significantly less efficient at inducing vascularization ($20 vs. 30 vessels, P <.05 ). These data imply that a locally elevated level of endostatin, achieved by rAAV transduction, can suppress tumor cell -induced angiogenesis in vivo in a paracrine fashion.
To evaluate whether elevated serum levels of endostatin could interfere with tumor-associated angiogenesis, 293-HuEndo cells (that secreted $300 ng /mL / 10 6 cells in 24 hours in vitro ) were injected (1Â10 7 ) into the hind muscle of nude mice. The implantation of these ''cellular protein factories'' resulted in elevated serum levels of endostatin ( Fig 5) . These levels rose within 24 hours after 293-HuEndo injection to almost 40 ng/mL and this level was maintained for at least 7 days. It should be noted that no detectable human endostatin levels were found in mice injected with 1Â10 7 293 parental cells or 293 cells stably expressing GFP. When parental HT29 cells were injected into such pretreated nude mice, the resultant number of induced blood vessels was significantly less than that observed when tumor cells were injected into untreated animals or mice that had been injected with 1Â10 7 293 cells stably expressing GFP (Fig 6) . The final aspect of the present investigation focused on the evaluation of the delivery of a transgene expressing HuEndo by direct intramuscular injection of rAAV vector and its effect on tumor-induced angiogenesis and tumor growth. There is a known delay in the onset of the expression of transgenes from AAV vectors, believed to be the consequence of vector DNA being gradually converted into double -stranded forms by leading strand synthesis before establishing stable gene expression. 21, 30 Such an expression profile also was observed in our studies when mice received an intramuscular injection of rAAV-HuEndo (Fig 7 ) . Plateau serum endostatin levels were reached 6-8 weeks after injection. The effect of rAAV was dose dependent with a high dose ( 1Â10 9 i.u. ) resulting in a serum endostatin level of $35 -40 ng /mL. This level was sufficient to have an antiangiogenic effect in vivo (Fig 8) . No detectable human endostatin levels were found in mice injected with 1Â10 9 control rAAV-GFP vectors. When HT29 cells were injected into nude mice with such serum endostatin levels, their ability to induce blood vessels was reduced significantly compared to that seen for HT29 cells injected into untreated control animals or mice that had been injected with rAAV-GFP.
To examine the impact of serum endostatin level on tumor growth, the HT29 xenograft tumor model was used. Due to Figure 8 Effect of elevated serum levels of endostatin on the number of vessels induced by HT29 cells as assayed in an intradermal angiogenesis assay. Nude mice were injected intramuscularly with 1Â10 9 i.u. of rAAV -HuEndo. Six weeks later 5Â10 4 HT29 cells were injected intradermally at four sites in the ventral surfaces of the nude mice. Three days later the skin was removed and the numbers of vessels induced were counted using a dissecting microscope. Each solid cycle represents one injection site; the bars show the median of 16 sites per group. P < .05, rAAV -HuEndo group versus untreated or rAAV -GFP groups. i.u. ) six weeks before injecting HT29 cells subcutaneously ( s.c. ) into nude mice. Animals were checked daily and emerging tumors were measured. The results showed that tumors in mice injected with the viral vector expressing human endostatin not only took significantly longer to appear but also that their growth, once established was significantly retarded compared to that of tumors grown in untreated animals or animals injected with the rAAV-GFP vector ( Fig 9A ) . To quantify this difference, both the time to initial tumor occurrence (reach a size of $200 mm 3 ) and the time to grow from a fixed size to one five times larger ( 200-1000 mm 3 ) were recorded and compared. Though all mice eventually developed tumors, those in the rAAV-HuEndo group took significantly longer to grow to the 200 -mm 3 size ( Fig 9B ) and to grow from 200 to 1000 mm 3 ( Fig 9C ) than did tumors in untreated and rAAV-GFP -treated animals.
The mice in the tumor growth study were killed when their tumors reached a size >1000 mm 3 . Serum endostatin levels were measured and tumor sections were prepared for histologic and immunohistochemical analysis. The results showed that serum endostatin levels remained high (44 ± 6.5 ng/mL ) at the time of termination of the rAAV-HuEndotreated mice (77 -121 days after vector injection ). Histological evaluation showed that the area of necrosis in tumors from rAAV-HuEndo -treated mice was significantly larger than that of tumors from untreated or rAAV-GFP -injected animals ( Table 1 ). CD31 staining of the non-necrotic areas revealed similar vessel densities in the rAAV-HuEndotreated and control groups. However, the functional vessel counts, as identified by Hoechst 33342 staining, were significantly reduced in tumors of the rAAV-HuEndotreated group ( Table 1) .
Discussion
Endostatin was first purified from a murine hemangioendothelioma cell line and identified as a 20 -kDa fragment of collagen XVIII. 10 It is an endogenous inhibitor of angio- following subcutaneous injection of 2Â10 6 HT29 cells into nude mice that were untreated or injected with 1Â10 9 i.u. of rAAV -Endo of rAAV -GFP or rAAV -HuEndo 6 weeks before. Solid cycles represent individual tumors; the bars show the median response. P < .05, rAAVHuEndo group versus untreated or rAAV -GFP groups. C: Median time ( bars ) for HT29 tumors to grow to five times the starting size in untreated mice or mice injected with 1Â10 9 i.u. of rAAV -GFP or rAAV -HuEndo 6 weeks before. Tumors were measured every 2 days. Each solid cycle represents one xenograft tumor. P < .05, rAAV -HuEndo group versus untreated or rAAV -GFP groups. 31 shown to inhibit the proliferation of endothelial cells and have a negative impact on the growth of metastases as well as primary tumors in a variety of preclinical cancer models when administered systemically. 10, 12, 31, 32 An important aspect of tumor growth inhibition by interference with the angiogenic process is the need for long -term suppression. Given the general difficulty of maintaining chronic serum levels of biologically active proteins, strategies to deliver endostatin via a gene therapy approach have been initiated. For example, nonviral endostatin gene transfer can cause antitumor effects in mice. 33 -35 But the injection of naked DNA or systemic administration of plasmids carrying the endostatin gene achieve only a transient low -level elevation of circulating endostatin. 33 -35 In contrast, high circulating endostatin levels sufficient to inhibit tumor growth in mice have been attained with adenoviral vector constructs. 16,36 -38 However, this application may be limited by its immunogenicity and toxicity. Adenovirus -based gene transfer induces inflammatory and immune responses that lead to loss of the transduced cell and result in transient gene expression and limited efficacy of repeated deliveries. 39 Even if the immune reactions could be minimized, the full potential for long -term expression is not realizable because the adenovirus cannot integrate. An alternative strategy, the use of the adeno -associated virus for endostatin gene transfer was explored in the present series of investigations.
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Recombinant viral vectors derived from the nonpathogenic parvovirus, adeno -associated virus, are modified such that all viral genes are replaced with an eukaryotic expression cassette. The absence of viral genes renders the rAAV less immunogenic than adeno vectors although immune responses to the vector and transgene may occur. 21, 40 Still viral particles have been shown to be stable and capable of efficient and prolonged transgene expression in a number of dividing and nondividing tissues in vivo. 18, 41 Skeletal muscle in particular has been used successfully for long -term expression of transgenes by rAAV. 21, 30, 42, 43 When this approach was taken in the present investigation, it was observed that a single intramuscular injection of the rAAVHuEndo vector could lead to elevated serum endostatin levels by 4 weeks after injection (Fig 7 ) . The endostatin levels reached a plateau value by 6 to 8 weeks (Fig 7) and were maintained as long as 4 months after injection. Because the goal of our study was to examine the efficacy of endostatin -mediated suppression of angiogenesis in a human xenograft tumor model, immunodeficient athymic nude mice had to be used. Although it is possible that the sustained expression of the HuEndo transgene by rAAV transduction was due to the lack of an immune response in the nude mice, this is highly unlikely. Indeed the experience with AAV vectors injected into skeletal muscle of small or large immunocompetent animals has shown that transgene expression may persist for years. 21, 44 Rather, two aspects of AAV biology are believed to contribute to the prolongation of transgene expression. The vector genome replicates as a large concatemer, either existing stably as a large episome or integrating randomly into the host genome. 45 Moreover, the vector avoids activation of destructive cytotoxic T-lymphocyte responses to antigenic transgene products, a problem for naked DNA and adenoviral vectors. 46, 47 Biological activity for the recombinant endostatin protein expressed by rAAV transduction was evaluated both in vitro and in vivo. A dose of 50 ng/ mL inhibited the growth and migration of both human (HUVEC ) and mouse ( MHE ) endothelial cells in vitro ( Figs 2 and 3 ) . Similar inhibitory effects in endothelial cells have been reported previously. 24 In addition, and more importantly, endostatin was found to have antiangiogenic activity in vivo. This was demonstrated in two ways. First, HT29 tumor cells that stably overexpress human endostatin induced significantly fewer blood vessels in an in vivo intradermal angiogenesis assay than did parental or GFP -transfected HT29 cells (Fig 4 ) . Second, elevated serum levels of human endostatin ( Fig 5 ) , achieved by injecting genetically engineered 293 cells that secreted human endostatin at a high level (300 ng/ d/million cells), effectively impaired the induction of blood vessels by HT29 tumor cells (Fig 6) . It is interesting to note that similar levels of angiogenic suppression were achieved by both these approaches even though the expression levels of the two clones were very different. The most likely explanation for this observation is that the HT29 -HuEndo cells lead to high local concentrations of endostatin whereas the 293 -HuEndo secret endostatin into the circulation.
Having established antiangiogenic activity in vivo, a gene delivery vehicle to achieve long -term production of endostatin and maintenance of elevated serum levels was developed. The results showed that a single intramuscular injection of 1Â10 9 i.u. rAAV-HuEndo could achieve a serum endostatin level of $40 ng/ mL ( Fig 7 ) . This moderate, but well-sustained level of endostatin level was sufficient to inhibit the tumor cell -induced angiogenic process ( Fig 8) as well as the initiation and subsequent growth of human colon cancer xenografts ( Fig 9, A -C ) . This represents the first demonstration of rAAV-mediated endostatin expression that results in tumor growth inhibition.
In our experiments a relatively low endostatin serum level ( $40 ng /mL ) was found to significantly inhibit tumor growth. A variety of factors may contribute to this. First, by using AAV we were able to maintain this serum endostatin level for a period of several months. This is quite different from the endostatin expression profiles achieved using other methods such as adenovirus, liposome delivery of plasmids, or naked plasmid DNA. Second, the time when endostatin serum levels were raised may be important ( in our studies human endostatin serum levels were raised and maintained before the tumor cells were implanted ). Third, the different tumor models that have been investigated may account for some differences in responses to endostatin.
Histological studies (Table 1 ) revealed that tumors taken from rAAV-HuEndo -treated mice demonstrated significantly greater amounts of necrosis than did similarsized tumors taken from untreated or control vector -injected mice. Further, although the microvessel densities were not different in tumors of the various groups, functional vessel counts were significantly reduced in tumors of the rAAV-HuEndo -treated group. These findings suggest that extended endostatin exposure may lead to malformed and /or malfunctioning blood vessels in tumors, such that the xenografts not only grew at a slower rate, but perhaps also switched to a less angiogenic form.
The antitumor effects observed in the present study occurred at endostatin levels lower than those reported in some other studies. 37, 38, 48 This difference likely is due to the fact that rAAV gene transfer and expression of endostatin causes a prolonged steady elevation of serum endostatin levels compared to the high initial peak and subsequent falloff in serum levels observed using adenovirus delivery vehicles. Also in the present studies, the tumors were introduced and initiated in an environment where the serum endostatin level was already elevated. This is likely to be the time when antiangiogenic agents are most effective. Still, these investigations provide clear evidence that the use of a rAAV to deliver the human endostatin protein can achieve in vivo antitumor effects in a human xenograft model. Further, although the treatment regimen examined impacted both tumor cell -induced angiogenesis and tumor growth, these treatment conditions were not optimized. Indeed it is probable that even greater efficacy could be achieved if the total dose of rAAV were increased or repeated administration of rAAV vector were used particularly if applied in concert with conventional anticancer treatments such as radiotherapy or chemotherapy. Finally, whereas long -term suppression of angiogenesis will be needed when applied in a cancer setting, concerns exist that extended antiangiogenic therapy may lead to adverse effects on physiologic angiogenesis. Consequently, the capability of providing the angiogenic suppression only when needed may prove important. To address this issue for rAAV-mediated antiangiogenic gene therapy and to test the utility of an AAV-based endostatin therapy against established tumors, vectors in which the expression of the transgene is controlled by a promoter that is regulated by an exogenous agent are currently being developed in our laboratory.
In summary, the present studies clearly demonstrate that a gene therapy approach using a rAAV to deliver the antiangiogenic protein can have significant utility in the suppression of both tumor-induced angiogenesis and growth and may provide an effective strategy for treating solid tumors.
